Page 31 - Program Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chemotherapy (CEP).  Noxopharm CEO Dr Graham Kelly said: “Our 4-pillars Veyonda strategy is behind an ambitious goal of bringing Veyonda to market as a general-purpose drug that boosts the effectiveness of common cancer therapies.  “One of those pillars, the CEP program, is looking at using Veyonda to make standard chemotherapy more effective in general, but to do it in a way that also makes it a lot safer.  “If we can achieve that, more patients should benefit with better responses and fewer side-effects.  “Potentially, it also expands the number of patients willing to undergo ch...

The Need for Comprehensive Diagnostics Remains as Cases Spike Once More FinancialBuzz.com News Commentary Share this article Share this article NEW YORK, April 20, 2021 /PRNewswire/ -- The Director of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and many other experts have warned that rapid reopening and lifting of pandemic restrictions in many states, as well as the proliferation of more contagious variants, will likely result in ongoing and increased spread of the virus in hot spots around the country. The pandemic remains a very real threat as the num...

Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline plc (NYSE: GSK) have provided an update on the VIR-7831 ...

DGAP-News: CureVac / Key word(s): Study CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma 04.02.2021 / 13:10 CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma - - Trial expansion focuses on advanced melanoma, an indication of high medical need TÜBINGEN, Germany / BOSTON, USA - February 4, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the start of an expansion of the ongoing Phase 1 study with its lead RNA-...

Share this article Share this article INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 sp...